SCHOTT Pharma AG & Co. KGaA
SCHOTT Pharma AG & Co. KGaA develops, manufactures, and sells drug containment solutions and delivery systems for injectable drugs for pharma, biotech, and life science industries worldwide. The company offers syriQ, a glass syringe for vaccines; syriQ BioPure, a glass syringe for biologics; syriQ BioPure silicone-free, a prefillable and silicone-free glass syringe for biologics; SCHOTT TOPPAC, a… Read more
SCHOTT Pharma AG & Co. KGaA (1SXP) - Total Assets
Latest total assets as of September 2024: €1.44 Billion EUR
Based on the latest financial reports, SCHOTT Pharma AG & Co. KGaA (1SXP) holds total assets worth €1.44 Billion EUR as of September 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
SCHOTT Pharma AG & Co. KGaA - Total Assets Trend (2020–2024)
This chart illustrates how SCHOTT Pharma AG & Co. KGaA’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
SCHOTT Pharma AG & Co. KGaA - Asset Composition Analysis
Current Asset Composition (June 2024)
SCHOTT Pharma AG & Co. KGaA's total assets of €1.44 Billion consist of 40.8% current assets and 59.2% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 1.6% |
| Accounts Receivable | €174.89 Million | 12.1% |
| Inventory | €140.44 Million | 9.7% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €1.12 Million | 0.1% |
| Goodwill | €29.35 Million | 2.0% |
Asset Composition Trend (2020–2024)
This chart illustrates how SCHOTT Pharma AG & Co. KGaA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: SCHOTT Pharma AG & Co. KGaA's current assets represent 40.8% of total assets in 2024, an increase from 40.1% in 2020.
- Cash Position: Cash and equivalents constituted 1.6% of total assets in 2024, down from 3.1% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, a decrease from 4.0% in 2020.
- Asset Diversification: The largest asset category is accounts receivable at 12.1% of total assets.
SCHOTT Pharma AG & Co. KGaA Competitors by Total Assets
Key competitors of SCHOTT Pharma AG & Co. KGaA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
OJsys Inc
PINK:OJSY
|
USA | $8.03 Million |
|
Beijing Centergate Technologies Holding Co Ltd
SHE:000931
|
China | CN¥3.82 Billion |
|
Blue Sail Medical Co Ltd
SHE:002382
|
China | CN¥16.46 Billion |
|
Andon Health Co Ltd
SHE:002432
|
China | CN¥28.98 Billion |
|
Allmed Medical Products Co Ltd Class A
SHE:002950
|
China | CN¥5.35 Billion |
|
Inix Technologies Holdings Bhd
KLSE:0094
|
Malaysia | RM72.53 Million |
|
Focus Point Holdings Bhd
KLSE:0157
|
Malaysia | RM328.19 Million |
|
Careplus Group Bhd
KLSE:0163
|
Malaysia | RM286.61 Million |
SCHOTT Pharma AG & Co. KGaA - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - SCHOTT Pharma AG & Co. KGaA generates 0.66x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, SCHOTT Pharma AG & Co. KGaA generates $ 10.38 in net profit.
SCHOTT Pharma AG & Co. KGaA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.35 | 1.33 | 1.72 |
| Quick Ratio | 1.03 | 0.94 | 1.32 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €153.12 Million | € 117.19 Million | € 231.50 Million |
SCHOTT Pharma AG & Co. KGaA - Advanced Valuation Insights
This section examines the relationship between SCHOTT Pharma AG & Co. KGaA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.48 |
| Latest Market Cap to Assets Ratio | 0.33 |
| Asset Growth Rate (YoY) | 17.1% |
| Total Assets | €1.44 Billion |
| Market Capitalization | $475.06 Million USD |
Valuation Analysis
Below Book Valuation: The market values SCHOTT Pharma AG & Co. KGaA's assets below their book value (0.33 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: SCHOTT Pharma AG & Co. KGaA's assets grew by 17.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for SCHOTT Pharma AG & Co. KGaA (2020–2024)
The table below shows the annual total assets of SCHOTT Pharma AG & Co. KGaA from 2020 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-06-30 | €1.44 Billion | +17.08% |
| 2023-06-30 | €1.23 Billion | +2.95% |
| 2022-06-30 | €1.20 Billion | +61.71% |
| 2021-06-30 | €739.89 Million | +24.14% |
| 2020-06-30 | €596.02 Million | -- |